Cytokinetics' (CYTK) shares plunge 11.9% after the company reported that an error in the Phase...

|By:, SA News Editor

Cytokinetics' (CYTK) shares plunge 11.9% after the company reported that an error in the Phase II trial of its Tirasemtiv treatment for Lou Gehrig's disease caused 58 subjects to incorrectly receive a placebo rather than the drug.